Clinical trial
Reversal of Ventricular Remodeling With Toprol-XL
NCT00038077 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00038077 |
|---|---|
| Title | Reversal of Ventricular Remodeling With Toprol-XL |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | Seloken ZOK/Toprol-XL, Placebo |
| Enrollment | 300 |
| Start date | Aug 1, 2001 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | May 29, 2002 |
| Last update posted | Nov 19, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: